What Makes Ivermectin a Potent Antiviral?

Originally published August 15, 2021

Updated on December 4, 2025, with new Latin American Spanish and Mandarin audio versions to help readers worldwide access this content.

🎧 ▶️ Press the play button below to listen in English.

🇪🇸 Spanish (Latinoamérica)

En este audio aprenderás cómo la ivermectina y otros mecanismos biológicos pueden influir en la respuesta antiviral del cuerpo según la evidencia científica disponible.

Presiona el botón de reproducir para escuchar.

🇨🇳 中文（简体）

本段音频将解释伊维菌素在抗病毒机制中的潜在作用，并概述目前实验室研究所显示的关键证据。

请按下方的播放按钮收听。

Introduction

Ivermectin has been widely discussed since the early phases of the COVID-19 pandemic, especially because it appears across multiple prevention and treatment protocols proposed by the Front Line COVID-19 Critical Care Alliance (FLCCC). These protocols include:

• I-CARE – Early Outpatient Treatment Protocol for COVID-19
• I-PREVENT – Prevention & At-Home Treatment Mass Distribution Protocol for COVID-19, Influenza and PSV Protection Protocol
• MATH+ –  Hospital Treatment Protocol for COVID-19 (Ivermectin included in the protocol)
• I-RECOVER – Management Protocol for Long Haul COVID-19 Syndrome (LHCS)
• I-RECOVER – Post-Vaccine Treatment

Its inclusion is due to its anti-inflammatory properties and its proposed antiviral mechanisms, which have been examined in laboratory, mechanistic, and clinical-observation–level studies.

This article explains how ivermectin works, what the referenced studies show, its safety profile, and key considerations for physicians and patients.

---

How SARS-CoV-2 Enters Cells — and Where Ivermectin Acts

All viruses rely on host cell machinery to reproduce. One of the pathways used by RNA viruses—including coronaviruses—is the Importin α/β1 nuclear transport system.

Certain viral proteins must enter the host cell nucleus to suppress antiviral defenses. To accomplish this, the virus binds to Importin α and Importin β1, forming a complex that moves through the nuclear pore complex (NPC).

Caly et al. demonstrated ivermectin’s inhibition of this transport

Caly and colleagues showed that ivermectin can bind Importin α and disrupt its ability to form the Importin α/β1 complex needed for viral nuclear entry.
Their in-vitro work demonstrated:

• Ivermectin destabilizes the Importin α/β1 heterodimer
• Viral proteins cannot efficiently enter the nucleus
• Antiviral responses of the host cell remain intact
• Viral replication in cell culture is significantly reduced

Reference: Caly L et al., Antiviral Research (2020)

Their schematic illustrates that ivermectin blocks the viral cargo from entering the nucleus, allowing the cell’s innate antiviral mechanisms to activate appropriately.

This mechanism does not target the virus directly, but rather modulates the host’s transport proteins. Because ivermectin acts on a host pathway, viral mutations (variants) are less likely to bypass the mechanism.

---

Additional Proposed Antiviral Mechanisms

A published in-silico analysis by Choudhury et al. found that ivermectin may also bind to several SARS-CoV-2–related enzymes and proteins:

• Viral replicase
• Viral protease
• Human TMPRSS2 (a surface protease important for viral entry)

These findings support the hypothesis that ivermectin has multifaceted antiviral potential, although in-silico work is predictive and not equivalent to clinical evidence.

Reference: Choudhury A et al., Future Virology (2021)

---

Spectrum of Antiviral Activity Observed in Preclinical Studies

Heidary & Gharebaghi reviewed studies describing ivermectin’s antiviral effects across a broad range of viruses. Laboratory data reported activity against:

• Yellow fever
• West Nile
• Dengue
• RSV
• Hendra virus
• Chikungunya
• Avian influenza A (H5N1)
• HIV-1
• Polyomavirus
• Venezuelan equine encephalitis virus
• Several coronaviruses, including SARS-CoV-2

These findings are preclinical and do not imply clinical effectiveness but highlight ivermectin’s broad biological targets.

Reference: Heidary & Gharebaghi, Journal of Antibiotics (2020)

---

Safety Profile of Ivermectin

A 2020 systematic review and meta-analysis examined the safety of standard and high-dose ivermectin across multiple indications.

Key conclusion:

“No difference in the severity of adverse events between standard (up to 400 μg/kg) and higher doses.”
— Navarro et al., Journal of Antimicrobial Chemotherapy (2020)

This dose range overlaps with FLCCC protocols (0.2–0.4 mg/kg).

Ivermectin has been:

• FDA-approved for strongyloidiasis and onchocerciasis
• Extensively used in mass drug administration programs in Africa for river blindness
• Added to the WHO List of Essential Medicines

Its humanitarian impact contributed to the 2015 Nobel Prize in Physiology or Medicine awarded to Campbell and Ōmura.

---

NIH Position on Ivermectin for COVID-19

As of February 11, 2021:

“There is insufficient evidence for the COVID-19 Treatment Guidelines Panel to recommend either for or against the use of ivermectin for the treatment of COVID-19.”
— NIH COVID-19 Treatment Guidelines Panel What makes Ivermectin a kick-as…

This classification is neutral and does not prohibit clinician-directed off-label use when medically justified.

---

Understanding Off-Label Use

The FDA allows physicians to prescribe FDA-approved medications for conditions outside their labeled indication when clinically appropriate.

Examples include:

• Tamsulosin and finasteride for kidney stones
• Widely adopted off-label uses in pediatrics, oncology, and critical care

Thus, ivermectin’s FDA approval for parasitic diseases does not restrict clinicians from considering it for other conditions based on clinical judgment.

FDA statement excerpt included in PDF

---

Clinical Evidence Landscape

A 2021 review by Kory et al. summarized emerging data at that time on ivermectin for prophylaxis and treatment.

Reference: Kory P et al., American Journal of Therapeutics (2021) What makes Ivermectin a kick-as…

The review compiled observational studies, small randomized trials, and mechanistic data. The authors proposed possible clinical utility but acknowledged evolving evidence.

Today, clinicians should review updated systematic reviews, evolving guideline positions, and newer large-scale clinical trials as they interpret earlier summaries.

---

Key Takeaways

• Mechanistic evidence shows ivermectin can inhibit viral nuclear import pathways in vitro.
• In-silico work suggests possible inhibition of viral enzymes and TMPRSS2.
• Preclinical antiviral activity has been reported across many viruses.
• Safety data indicate similar adverse-event rates between standard and higher doses in diverse clinical settings.
• Clinical evidence remains mixed, and authoritative bodies call for more high-quality data.
• Off-label prescribing remains permissible when guided by physician judgment.

---

Medical Disclaimer

This article summarizes mechanistic and preclinical findings from referenced studies. It does not provide medical advice or endorse any specific treatment. Clinical decisions must be made by licensed healthcare professionals who consider individual patient circumstances, regulatory guidance, and the most current evidence.

Don’t Get Sick!

Medically Reviewed by Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and

Related:

1. SARS-CoV-2 Spike Protein Cause Red Blood cell Clumping, and Ivermectin Prevents it
2. The NFL is giving their players IVERMECTIN as a prophylactic AND to prevent “positive” Covid tests
3. A new study shows a 100% decreased hospitalization rate with regular ivermectin use
4. Ivermectin prevents binding to human cells by blocking the spike protein
5. The many problems of the Ivermectin study in the NEJM
6. Japanese company announces Ivermectin has antiviral properties
7. City-wide use of Ivermectin lowered COVID-19 cases, hospitalizations and deaths in Itajaí, Brazil
8. What makes Ivermectin a kick-ass antiviral?
9. Where to Get Ivermectin
10. How to get Ivermectin
11. Bayes Theorem Confirms Meta-analysis of Ivermectin’s Effectivity against COVID-19
12. News that ivermectin overdose is clogging up hospitals is not true
13. Ivermectin vs Remdesivir for COVID-19
14. Solved! The Ivermectin African Enigma
15. IVMMETA.COM: A website of studies on Ivermectin’s efficacy
16. Ivermectin is effective against Influenza and Cold Virus In Vitro

References:

1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3. PMID: 32251768; PMCID: PMC7129059.
2. Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? Antiviral Res. 2012 Sep;95(3):202-6. doi: 10.1016/j.antiviral.2012.06.008. Epub 2012 Jun 28. PMID: 22750233.
3. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593-602. doi:10.1038/s41429-020-0336-z
4. Miriam Navarro, Daniel Camprubí, Ana Requena-Méndez, Dora Buonfrate, Giovanni Giorli, Joseph Kamgno, Jacques Gardon, Michel Boussinesq, Jose Muñoz, Alejandro Krolewiecki, Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, Volume 75, Issue 4, April 2020, Pages 827–834, https://doi.org/10.1093/jac/dkz524.
5. Kory, Pierre MD^1,*; Meduri, Gianfranco Umberto MD²; Varon, Joseph MD³; Iglesias, Jose DO⁴; Marik, Paul E. MD. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19, American Journal of Therapeutics: May/June 2021 – Volume 28 – Issue 3 – p e299-e318 doi: 10.1097/MJT.0000000000001377
6. Choudhury A, Das NC, Patra R, et al. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virol. 2021;10.2217/fvl-2020-0342. doi:10.2217/fvl-2020-0342

As an Amazon Associate, I earn from qualifying purchases.